Articles tagged "Induction therapy"

2019 American Transplant Congress
Infective Complications after Renal Transplantation – A Single Centre Experience Comparing Alemtuzumab to Basiliximab Induction
R. Czajka, M. Welberry Smith, M. Gittus, E. Lindley, M. Vernon
Renal Medicine, St James' University Hospital, Leeds, United Kingdom
*Purpose: Our centre predominantly uses alemtuzumab as induction immunosuppression for renal transplantation. We examined infective complications after renal transplantation, comparing different induction, and maintenance, immunosuppression…
2019 American Transplant Congress
Type of Induction Does Not Impact Patient or Kidney Allograft Survival in Simultaneous Liver and Kidney Transplant Recipients in the United States
S. Riad¹, N. Lim², S. Jackson³, J. Lake²
¹University of Minnesota, Minneapolis, MN, ²Medicine, University of Minnesota, Minneapolis, MN, ³Complex Care Analytics, Fairview Health Services, Minneapolis, MN
*Purpose: Induction practices vary widely in the United States for patients undergoing simultaneous liver and kidney (SLK) transplantation. We examined the impact of induction type…
2019 American Transplant Congress
ECDI-Treated Donor Leukocytes in Primate Cardiac Allograft Recipients
Z. Alikhassy Habibabady¹, T. Zhang², W. Sun², X. Cheng², L. Burdorf¹, I. Tatarov², S. Sendil², I. Behroozfard², B. Cerel¹, D. Parsell², R. N. Pierson III¹, X. Luo³, A. M. Azimzadeh¹
¹Surgery, Massachusetts General Hospital and Harvard School of Medicine, Boston, MA, ²Surgery, University of Maryland School of Medicine, Baltimore, MD, ³Duke Transplant Center, Duke University, Durham, NC
*Purpose: Ethyl carbodiimide (ECDI)-fixed donor leukocytes exhibit tolerogenic immunomodulation in murine models of autoimmunity and transplantation, and nonhuman primate islet transplantation. Here in pilot studies…
2019 American Transplant Congress
A Prospective Randomized Multicenter Trial (B E S T Trial) of Belatacept-Based C N I- and Corticosteroid-Free Immunosuppression: Final Two Year Results
D. B. Kaufman¹, A. R. Shields², J. P. Leone³, A. Wiseman⁴, A. J. Matas⁵, P. West-Thielke⁶, J. Lipscomb², E. King², R. R. Alloway⁷, E. S. Woodle for the BEST Study Group²
¹University of Wisconsin, Madison, WI, ²University of Cincinnati, Cincinnati, OH, ³Tampa General, Tampa, FL, ⁴University of Colorado School of Medicine, Denver, CO, ⁵University of Minnesota, Minneapolis, MN, ⁶University of Illinois, Chicago, Chicago, IL, ⁷University of Cincinnati, Cincinnati, WI
*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal Trial) is a prospective, randomized, multi-center trial designed to compare two belatacept (BELA)-based calcineurin inhibitor-free (CNI), early…
2019 American Transplant Congress
Rabbit Anti-Thymocyte Globulin (rATG) Induction in Heart Transplant Recipients at High Risk for Rejection
B. Kitto¹, B. Baetz¹, S. Krim², H. Patel², S. Mandras², S. Desai², C. Eiswirth², H. Ventura², S. Thai¹
¹Pharmacy, Ochsner Medical Center, New Orleans, LA, ²Heart Transplant, Ochsner Medical Center, New Orleans, LA
*Purpose: To assess the safety and efficacy of rATG induction in heart transplant recipients at high risk for rejection.*Methods: This was a single-center, retrospective study…
2019 American Transplant Congress
Outcomes Of Dosing Weight Selection On Rabbit Anti-thymocyte Globulin Induction Immunosuppression In High-risk, Obese Renal Transplant Recipients
A. C. Cordry¹, K. Trobaugh¹, L. Ramsey², A. L. Castellanos³, H. Fattah³, T. Rendulic¹
¹Pharmacy, University of Kentucky HealthCare, Lexington, KY, ²University of Kentucky College of Pharmacy, Lexington, KY, ³Nephrology, University of Kentucky HealthCare, Lexington, KY
*Purpose: There are limited data regarding the optimal weight-based dosing strategy for rabbit anti-thymocyte globulin (rATG) induction in renal transplantation. At our center, rATG is…
2019 American Transplant Congress
Antithymocyte Globulin is Associated with Mature T Cell Phenotypes and Decreased Risk of Non-EBV Infections in Transplanted Children
B. I. Shaw¹, L. Stempora¹, C. Chan¹, R. B. Ettenger², P. C. Grimm³, H. Lee¹, E. F. Reed², M. M. Sarwal⁴, B. L. Warshaw⁵, C. Zhao¹, O. M. Martinez³, A. D. Kirk¹, E. T. Chambers¹
¹Pediatrics/Surgery, Duke University, Durham, NC, ²Pediatrics, University of California, Los Angeles, Los Angeles, CA, ³Pediatrics/Surgery, Stanford University, Palo Alto, CA, ⁴Pediatrics/Surgery, University of California, San Francisco, San Francisco, CA, ⁵Pediatrics, Emory University, Atlanta, GA
*Purpose: Depletional induction therapies are known to reduce the rate of acute rejection; yet data from the US Renal Data System have shown that use…
2019 American Transplant Congress
Induction Therapy in Elderly Kidney Transplant Recipients with Low Immunological Risk
C. Masset¹, J. Boucquemont², V. Garrigue³, M. Ladrière⁴, F. Buron⁵, E. Cassuto⁶, Y. Foucher², J. Dantal¹
¹University Hospital of Nantes, Nantes, France, ²University of Nantes, Nantes, France, ³University Hospital of Montpellier, Montpellier, France, ⁴University Hospital of Nancy, Nancy, France, ⁵University Hospital of Lyon, Lyon, France, ⁶University Hospital of Nice, Nice, France
*Purpose: Thymoglobulin (ATG) and Basiliximab (BSX) lead to similar rejection rates in low immunological risk patients. ATG seems to be associated with infectious and malignancy…
2019 American Transplant Congress
Outcomes of Induction Therapy with Bortezomib and High-Dose Intravenous Immunoglobulin for Kidney Transplantation with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies
Y. Miyauchi, T. Noda, N. Miura, T. Kikugawa, T. Saika
Department of Urology, Ehime University, Toon, Japan
*Purpose: Preformed donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) are known to increase the risk of antibody-mediated rejection (ABMR) and graft failure. However, effective methods…
2019 American Transplant Congress
Allogenic Islets Cure Diabetes Following Transplantation in Omental Pouch in a Non-Human Primate Model
J. Lei¹, H. Deng¹, K. Lee¹, C. Peters¹, G. Rickert¹, R. Ivy¹, M. Coronel², E. Yolcu³, H. Shirwan⁴, A. García⁵, J. Markmann¹
¹Surgery, Massachusetts General Hospital, Boston, MA, ²Surgery, Georgia Institute of Technology, Atlanta, GA, ³Institute for Cellular Therapeutics, University of Louisville School of Medicine, louisville, KY, ⁴Department of Microbiology and Immunology, University of Louisville School of Medicine, louisville, KY, ⁵School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA
*Purpose: In the current standard clinical transplant approach, islet cells are administered intravenously into the portal system where they lodge in the liver. This approach…